AstraZeneca’s COVID-19 vaccine holds up in an updated analysis of trial data
The redo came after a safety committee raised concerns over the data used in earlier results
![AstraZeneca's COVID-19 vaccine in boxes](https://i0.wp.com/www.sciencenews.org/wp-content/uploads/2021/03/032521_eg_astrazeneca_feat.jpg?fit=1030%2C580&ssl=1)
AstraZeneca’s primary analysis shows that the company’s COVID-19 vaccine (shown) has an efficacy of 76 percent. An interim analysis had previously found the vaccine had an efficacy of 79 percent.
Ian Forsyth/Getty Images